Topic: On Tuesday, Feb. 11, 2020, Dr. Patrick Forde, a thoracic oncologist at Johns Hopkins Medicine, discussed his clinical trial “Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma.” The trial, which consists of administering one or two immunotherapeutic agents pre-operatively (nivolumab alone, or nivolumab in combination with ipilimumab), is currently enrolling participants.
About the Speaker: Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Associate Member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director of Clinical Research for lung cancer, mesothelioma, and other thoracic cancers at Johns Hopkins. He is also a member of the Board of Directors of the Mesothelioma Applied Research Foundation.
